Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does REMDESIVIR Cause Bronchopulmonary aspergillosis? 63 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 63 reports of Bronchopulmonary aspergillosis have been filed in association with REMDESIVIR (Veklury). This represents 0.6% of all adverse event reports for REMDESIVIR.

63
Reports of Bronchopulmonary aspergillosis with REMDESIVIR
0.6%
of all REMDESIVIR reports
34
Deaths
29
Hospitalizations

How Dangerous Is Bronchopulmonary aspergillosis From REMDESIVIR?

Of the 63 reports, 34 (54.0%) resulted in death, 29 (46.0%) required hospitalization, and 11 (17.5%) were considered life-threatening.

Is Bronchopulmonary aspergillosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for REMDESIVIR. However, 63 reports have been filed with the FAERS database.

What Other Side Effects Does REMDESIVIR Cause?

Off label use (1,092) Alanine aminotransferase increased (1,047) Death (808) Aspartate aminotransferase increased (713) Bradycardia (652) Acute kidney injury (605) Covid-19 (570) Drug ineffective (497) Liver function test increased (447) Respiratory failure (394)

What Other Drugs Cause Bronchopulmonary aspergillosis?

TACROLIMUS (968) PREDNISONE (967) DEXAMETHASONE (854) CYCLOPHOSPHAMIDE (824) METHYLPREDNISOLONE (794) PREDNISOLONE (704) MYCOPHENOLATE MOFETIL (702) RITUXIMAB (606) CYCLOSPORINE (583) METHOTREXATE (553)

Which REMDESIVIR Alternatives Have Lower Bronchopulmonary aspergillosis Risk?

REMDESIVIR vs REMERON REMDESIVIR vs REMICADE REMDESIVIR vs REMIFENTANIL REMDESIVIR vs REMIMAZOLAM REMDESIVIR vs REMODULIN

Related Pages

REMDESIVIR Full Profile All Bronchopulmonary aspergillosis Reports All Drugs Causing Bronchopulmonary aspergillosis REMDESIVIR Demographics